Dietary Fat Increases High Density Lipoprotein (HDL) Levels Both by Increasing the Transport Rates and Decreasing the Fractional Catabolic Rates of HDL Cholesterol Ester and Apolipoprotein (Apo) A-I

Presentation of a New Animal Model and Mechanistic Studies in Human Apo A-I Transgenic and Control Mice

* Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York 10021-6399; and * Arizona Center on Aging, Tucson, Arizona 85719

Abstract

In humans, diets high in saturated fat and cholesterol raise HDL-cholesterol (HDL-C) levels. To explore the mechanism, we have devised a mouse model that mimics the human situation. In this model, HuA1Tg and control mice were studied on low fat (9%) and high fat (41%) diets. The mice responded to increased dietary fat by increasing both HDL-C and apo A-I levels, with a greater increase in HDL-C levels. This was compatible with an increase in HDL size observed by nondenaturing gradient gel electrophoresis. Turnover studies with doubly labeled HDL showed that dietary fat both increased the transport rate (TR) and decreased the fractional catabolic rate (FCR) of HDL cholesterol ester (CE) and apo A-I, with the largest effect on HDL CE TR. The latter suggested that dietary fat increases reverse cholesterol transport through the HDL pathway, perhaps as an adaptation to the metabolic load of a high fat diet. The increase in apo A-I TR by dietary fat was confirmed by experiments showing increased apo A-I secretion from primary hepatocytes isolated from animals on the high fat diet. The increased apo A-I production was not associated with any increase in hepatic or intestinal apo A-I mRNA, suggesting that the mechanism of the dietary effect was posttranscriptional, involving either increased translatability of the apo A-I mRNA or less intracellular apo A-I degradation. The dietary fat-induced decrease in HDL CE and apo A-I fractional catabolic rate may have been caused by the increase in HDL particle size, as was suggested by our previous studies in humans. In summary, a mouse model has been developed and experiments performed to better understand the paradoxical HDL-raising effect of a high fat diet. (J. Clin. Invest. 1993; 91:1665–1671.) Key words: high density lipoprotein • high fat • turnover • particle size distribution • metabolism • apolipoprotein A-I • diet responsiveness

Introduction

In most societies today, there is a well-known inverse correlation between coronary heart disease risk and HDL cholesterol (HDL-C) levels (1–3). However, paradoxically, diets high in saturated fat and cholesterol, which increase atherosclerosis risk, raise HDL-C levels (4–9). To explore the mechanism for this phenomenon and perhaps gain greater insight into the role of HDL in heart disease, in a previous human metabolic study (9), we measured the turnover of the major HDL apolipoproteins, apo A-I and apo A-II, in 13 subjects consuming low fat (9%)-low cholesterol (40 mg/1,000 kcal) and high fat (42%)-high cholesterol (215 mg/1,000 kcal) diets. The dietary fat challenge increased HDL-C 40%, apo A-I 30% (both P < 0.001), with no change in apo A-II levels. The turnover studies indicated a 17% increase in apo A-I transport rate (TR) and a 10% decrease in apo A-I fractional catabolic rate (FCR). Individual changes in HDL-C levels correlated with changes in apo A-I TR (r = 0.79, P < 0.001) but not FCR (r = −0.04). This study suggested that dietary fat both increases the TR and decreases the FCR of apo A-I with perhaps a larger effect on the TR (9).

Since clinical studies do not allow further examination of how dietary fat influences apo A-I metabolism nor do they permit studies of HDL CE metabolism, in the current study, to pursue these questions, an animal model was created. Mice were used because of the availability of human apo A-I transgenic (HuA1Tg) lines (10, 11). These animals express significant amounts of human apo A-I in plasma, and for reasons not yet understood, they have greatly diminished mouse apo A-I levels (11–13). Accompanying this exchange of human for mouse apo A-I is a change from normal mouse HDL, which has a single major size distribution of HDL particles to human-like HDL characterized by two or more major size distributions, principally HDL3a and HDL3b (11–13). Thus, HuA1Tg mice might be a better model in which to study the dietary fat-HDL relationship.

As in the human metabolic study, mice were fed low fat (9%)-low cholesterol (57 mg/1,000 kcal) and high fat (41%)-high cholesterol (437 mg/1,000 kcal) diets. In contrast to previously used high-fat-high cholesterol diets that have lowered HDL-C and apo A-I levels in some strains of mice.

1. Abbreviations used in this paper: CE, cholesterol ester; FCR, fractional catabolic rate; GGE, gradient gel electrophoresis; HDL-C, HDL cholesterol; TR, transport rate.
The dietary fat challenge raised HDL-C and apo A-I levels, as observed in humans (4–9), allowing detailed examination of the mechanism(s) for this dietary fat effect in the animal model.

Methods

Transgenic mice. One line of human apo A-I transgenic mice (line 179), which was previously described (10), was used. The line was created by injecting an 11.5-kb human apo A-I genomic fragment extending from 5.5 kb 5′ to 3.8 kb 3′ into the gene of F1 (C57BL/6J × CBA/J) fertilized eggs. The founder mouse was mated to F1s of the same genetic background, and transgenic offspring were similarly mated. Comparisons in metabolic studies were with nontransgenic litter mates. Whereas the endogenous mouse apo A-I gene is expressed equally in the liver and intestine, the human apo A-I transgene is expressed only in the liver in this line of mice (10).

Diets. The mice were fed two contrasting diets. The low fat-low cholesterol diet was rodent Chow (no. 5001;Ralston-Purina, St. Louis, MO). Its composition was (wt/wt): 4.5% fat, 59.8% carbohydrate, 23.4% protein, 5.0% fiber, 7.3% minerals, added vitamins A, D, and E, and 0.02% cholesterol. Fats provided 9% of the calories, equally divided between saturated, monounsaturated, and polyunsaturated fats (kindly analyzed by Dr. Lisa Hudgins [15]), and there was 57 mg/1,000 kcal of cholesterol. The high fat-high cholesterol diet was a milk fat based diet made for us (TD88813; Teklad Premier Laboratory Diets, Madison, WI). Its composition was (wt/wt): 21.2% fat, 49.1% carbohydrate, 19.8% protein, 5.0% fiber, 3.5% minerals, 0.4% CaCO3, 1% vitamin mix, 0.004% antioxidant, and 0.2% cholesterol. Fats provided 41% of the calories, with 27% saturated, 12% monounsaturated, and 2% polyunsaturated, and there was 437 mg/1,000 kcal of cholesterol. The cholesterol content of both diets was verified by gas chromatography. The fat content of the high-fat-high cholesterol diet corresponds to the 50th percentile of American dietary intake observed in the Lipid Research Clinic Study and the 75th percentile of intake in the most recent National Health and Nutrition Examination Survey (16, 17).

Blood and tissue sampling protocol. Animals were placed in metabolic cages in animal rooms with alternating 12-h periods of light (7 a.m.–7 p.m.) and dark (7 p.m.–7 a.m.) with ad lib access to food and water. For blood sampling, mice were fasted overnight and the animals bled the next morning from the retroorbital plexus under methoxyflurane anesthesia. Blood was collected into a tube containing 6 μl of EDTA (0.5 M). Plasma was separated by centrifugation at 1,875 g for 15 min and kept at 4°C until analysis. Where indicated, fasted animals were subjected to liver biopsy through a midline incision under anesthesia with 2.5% Avertin (0.02 ml/g body wt). The liver tissue (50–100 mg) was frozen immediately in liquid nitrogen and stored at −70°C. At the end of each diet study, the animals were fasted overnight and anesthetized with 2.5% Avertin. The liver and total small intestine were obtained, frozen immediately, and stored as above.

Plasma HDL-C and apo A-I analyses. HDL-C levels were determined by measuring cholesterol either in the d > 1.063 g/ml infranatant after air-drying ultracentrifugation, as previously described (10), or in the supernatant after precipitation of the other lipoproteins by dextran sulfate. The latter involved adding 11 μl of dextran sulfate Mg2+- solution (10 g/liter dextran sulfate, mol wt 50,000, 0.5 mol/liter Mg2+, buffered [no. 352-3; Sigma Immunochemicals, St. Louis, MO]) to 60 μl of plasma. This procedure was validated by immunochemical methods by showing that it did not precipitate apo A-I, but precipitated 96% of apo B. The particular method used for HDL-C determination in a given experiment is indicated. Cholesterol was determined enzymatically using reagents (no. 236691; Boehringer). In the HDL fraction, free cholesterol and total cholesterol (after saponification) were measured by gas chromatography with coprostanol as an internal standard. The cholesterol ester (CE) was taken as the difference between the two. Mice apo A-I levels were quantified by rocket immunoelectrophoresis using a polyclonal anti–mouse apo A-I antibody prepared in cynomolgus monkeys (generously provided by Dr. George Melchior, Upjohn Company, Kalamazoo, MI) as previously described (10, 12, 13). Human apo A-I levels were measured by enzyme-linked immunosorbent assay using a polyclonal goat anti–human apo A-I antibody, which was a gift from Dr. Peter Herbert, Miriam Hospital (Providence, RI) as previously described (10, 18). There was essentially no cross-species reactivity for either antibody.

In vivo HDL turnover studies. HDL doubly labeled in its apo A-I and cholesterol ester moieties was prepared as previously described (12, 13, 19–21). We previously showed that human and mouse apo A-I have the same rate of disappearance from the plasma of HuATg and control mice (10). Therefore, turnover studies in the current experiments were done only with radioiodinated human apo A-I. HDL CE was labeled with [3H]cholesterol oleoyl ether that had been dissolved in intralipid and transferred into HDL by CETP from d > 1.25 g/ml rabbit plasma (12, 13, 21). Mice were injected in the femoral vein with doubly labeled HDL (2–4 μg of [125I]human apo A-I and 100,000–200,000 dpm of [3H]cholesterol oleoyl ether). The injected HDL mass was < 5% of the mouse HDL pool (12, 21). Blood (50 μl) was taken from the retroorbital plexus under methoxyflurane anesthesia at 10 min, 90 min, 3 h, 8 h, and 28 h for determination of radioactivity. The FCRs for apo A-I and HDL CE were calculated from the plasma decay curves of [125I]apo A-I and [3H]cholesterol oleoyl ether assuming a two-pool model by the Matthews method (22).

HDL particle size determination. HDL particle size distribution was determined by nondenaturing gradient gel electrophoresis (GGE) as previously described (23, 24). In a 175-μl airfuge tube, 40 μl of plasma was adjusted to density 1.21 g/ml with 1.35 g/ml KBr, and this was overlaid with 50 μl of 1.21 g/ml KBr (1 mM EDTA). After ultracentrifugation at 100,000 g for 5 h (Airfuge, Beckman), 30 μl was aspirated from the top of the tube and electrophoresed in nondenaturing 4–30% polyacrylamide gradient gels (PA A 4/30; Pharmacia LKB, Piscataway, NJ) for 20 min at 70 V and then for 18–24 h at 125 V. Gels were fixed, stained, destained, and scanned as previously described (24). Scans were analyzed by Gaussian modeling and Stokes’ radii of HDL particles determined by comparing migration distances to those of particles of known size (24).

In vitro apo A-I production. Apo A-I production was determined in primary hepatocytes from mice fed the low fat-low cholesterol and high-fat-high cholesterol diets. Mice were weaned and then fed the diets for 4 wk. Animals were fasted for 4 h under methoxyflurane anesthesia with 5% sodium pentobarbital, and hepatocytes prepared by minor modifications of the method described by Sparks (25). The portal vein was cannulated and the liver was first perfused with a calcium-free isotonic buffer at 37°C for 10–15 min, and then perfused with a buffer containing 5 mM CaCl2 and 0.075% (wt/vol) collagenase (Boehringer Mannheim) for 30 min. After perfusion, the liver was gently disaggregated and the cells suspended in calcium-free buffer. The cells were washed with PBS and M199 (Sigma Immunochemicals), and dead cells were separated by centrifugation in 50% colloidal polyvinyl pyrrolidone–coated silica (percoll; Sigma Immunochemicals). Cell viability was assured by trypan blue staining and 500,000 live cells were plated on a 35-mm plate coated with poly-d-lysine. The culture medium was changed after 4 h incubation at 37°C. The next day, the cells were washed with M199, and fresh culture medium containing 100 μCi/ml of [3H]methionine was added and the cells incubated for 40, 60, 90, and 120 min at 37°C. After incubation, the medium was removed, the cells were washed twice with PBS, and then solubilized with 0.1 N NaOH. Cell protein was determined using the detergent-compatible protein assay (Bio Rad Laboratories, Richmond, CA) using BSA as a standard. 300 μl medium from each plate was used for immunoprecipitation using a mono-specific goat anti–human apo A-I antibody that does not bind to mouse apo A-I. Brieﬂy, an equal volume of protein–A binding buffer (Pierce Chemical Co., Rockford, IL) was mixed with the medium in a 1.5-ml Eppendorf tube. To this was added 15 μl anti–human A-I antisera, and the tubes were placed on a rocker at 4°C for 16 h. The next day, 15 μl of rabbit anti–goat IgG (Pierce Chemical Co.) was added and the tubes were incubated for 2 h at 4°C. 60 μl of a 20% protein-A Sepharose
suspension (Sigma Immunochemicals) was then added, and the tubes were incubated an additional 2 h. The protein-A pellets were then washed by centrifugation three times, each with 500 μl binding buffer. After washing, a 26-gauge needle was used to aspirate the last of the buffer from the protein-A pellets by placing it directly into the resin. To the washed pellets was added 60 μl of nonreducing SDS sample buffer (containing no β-mercaptoethanol). The samples were boiled and centrifuged, and then 50 μl of the supernatant was loaded onto a 12% SDS-PAGE (29:1 acrylamide/Bis) gel (6% stacking gel), and electrophoresed at 100 V for 5 h. The gels were then stained with Coomassie blue, destained, and treated with EN3HANCE (New England Nuclear, Boston, MA), dried, and exposed to Kodak XAR film. After autoradiography, the gel regions corresponding to apo A-I (27 kD) was excised, solubilized, and counted (26).

Quantitation of apo A-I mRNA levels. Human and mouse hepatic and mouse intestinal apo A-I mRNA abundance was measured using the solution hybridization RNase protection method previously described (27). RNA was isolated by the method of Chomczynski and Sacchi (28). 5 μg of total RNA was hybridized in solution to each riboprobe, and the RNase protected fragments collected on glass-fiber filters and counted (27). Background values for the human riboprobe using mouse hepatic RNA and for the mouse riboprobe using HepG2 cell (human) RNA were each < 0.3% of the total 32P-labeled probe input.

Statistical analysis. The Student's paired t test was used to compare values in animals before and after the diet. An unpaired Student's t test was used to compare values in groups of animals fed different diets. Statistical significance was defined as P < 0.05. Results are presented as mean±SE.

Results

The effect of the high-fat-high cholesterol diet on HDL-C and apo A-I levels in the mouse was determined as follows: 10–15-wk-old male HuAITg mice and nontransgenic litter mates were fed the high-fat-high cholesterol diet for 5 wk and another group of HuAITg mice were kept on the low-fat-low cholesterol diet for the same time period. Feedings were adjusted three times weekly based on measured food consumption to ensure equal intake among the three groups of animals throughout the 5-wk study period. From the beginning to the end of the experiment, in the HuAITg mice the high-fat-high cholesterol diet increased HDL-C 65%, human apo A-I 41%, and mouse apo A-I 48%. In the control mice, the high fat-high cholesterol diet increased HDL-C 53% and mouse apo A-I 24%. There were no changes in HDL-C or apo A-I levels in the HuAITg mice maintained on the low-fat-low cholesterol diet during the experimental period (Table 1). Thus, mice exposed to a high fat-high cholesterol diet respond by increasing HDL-C and apo A-I with a greater increase in HDL-C levels.

The mice were then used to explore the mechanism of the dietary fat effect on HDL. HuAITg and control male mice of 12–16 wk of age were fed either the low-fat-low cholesterol or high-fat-high cholesterol diet for 4 wk and an HDL turnover study was performed. HDL was doubly labeled with [125I]apo A-I and [3H]cholesteryl oleyl ether, injected intravenously, and the disappearance of plasma radioactivity was measured. The methods used to calculate HDL CE FCR and apo A-I FCR; these multiplied by the pool sizes (as reflected by the plasma concentration of HDL CE and total apo A-I, respectively) estimated the TRs as summarized in Table II. In HuAITg mice the high fat-high cholesterol diet decreased the HDL CE FCR (28%) and the apo A-I FCR (26%) and increased the HDL CE TR (61%) and apo A-I TR (30%). In control mice, the high-fat-high cholesterol diet decreased the HDL CE FCR (25%) and apo A-I FCR (24%) and increased the HDL CE TR (47%) and apo A-I TR (25%). Both HuAITg and control mice responded to the high fat diet by decreasing HDL CE and apo A-I FCR and increasing their TRs, with the effect on TR greater than on FCR for HDL CE. The dietary effect on FCR was equal for HDL CE and apo A-I, but its effect on TR was greater for HDL CE than apo A-I.

GGE was then used to study the effect of the high-fat-high cholesterol diet on HDL particle size distribution. On the low fat-low cholesterol diet, HuAITg mouse HDL consists primarily of two distinct HDL subpopulations with particle diameters of 11.0 and 9.3 nm, corresponding to human HDL2b and HDL3a. After the high fat-high cholesterol diet, there is an increase mainly in the HDL2b and even larger HDL subfractions (Fig. 1A). On the low fat-low cholesterol diet, control mouse HDL consists primarily of a single size population with a particle diameter of 9.8 nm. After the high-fat-high cholesterol diet, the HDL size distribution still seems to show one major peak, but the peak is broadened and skewed to larger particle diame-

Table I. Effects of Diet on HDL Cholesterol and Apo A-I Levels

<table>
<thead>
<tr>
<th>Mice</th>
<th>HDL-C*</th>
<th>Human Apo A-I</th>
<th>Mouse Apo A-I</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/dl</td>
<td>mg/dl</td>
<td>mg/dl</td>
</tr>
<tr>
<td></td>
<td>Before</td>
<td>After Percent increase</td>
<td>Before</td>
</tr>
<tr>
<td>HuAITg (n = 5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low → high fat</td>
<td>103±7</td>
<td>170±16$^4$ 65%</td>
<td>244±7</td>
</tr>
<tr>
<td>Controls (n = 6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low → high fat</td>
<td>51±2</td>
<td>78±3$^3$ 53%</td>
<td>—</td>
</tr>
<tr>
<td>HuAITg (n = 6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low → low fat</td>
<td>89±4</td>
<td>87±5</td>
<td>—</td>
</tr>
</tbody>
</table>

* HDL-C levels were determined by measuring cholesterol in the d > 1.063 g/ml infranatant after airfuge ultracentrifugation.

$^4 P = 0.059$

$^5 P < 0.05$

$^6 P < 0.01$

$^7 P < 0.005$

Significance of the difference between the end and the beginning of the experimental period.
Table II. Effects of Diet on HDL Metabolism

<table>
<thead>
<tr>
<th>Mice</th>
<th>HDL-C*</th>
<th>HDL CE FCR</th>
<th>HDL CE TR</th>
<th>Apo A-1</th>
<th>Apo A-1 FCR</th>
<th>Apo A-1 TR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/dl</td>
<td>pools/h</td>
<td>U</td>
<td>mg/dl</td>
<td>pools/h</td>
<td>U</td>
</tr>
<tr>
<td>HuAITg (n = 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chow diet</td>
<td>103±7</td>
<td>0.110±0.003</td>
<td>8.4±0.7</td>
<td>326±20</td>
<td>0.106±0.009</td>
<td>34.4±3.5</td>
</tr>
<tr>
<td>High fat diet</td>
<td>220±25¶</td>
<td>0.079±0.009¶</td>
<td>13.5±0.2²</td>
<td>570±40²</td>
<td>0.078±0.008²</td>
<td>44.3±4.6²</td>
</tr>
<tr>
<td>Control (n = 3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chow diet</td>
<td>54±3</td>
<td>0.182±0.009</td>
<td>7.3±0.2</td>
<td>168±12</td>
<td>0.105±0.005</td>
<td>17.6±1.1</td>
</tr>
<tr>
<td>High fat diet</td>
<td>103±5‖</td>
<td>0.137±0.005‖</td>
<td>10.7±0.8²</td>
<td>275±5²</td>
<td>0.079±0.003²</td>
<td>21.8±0.1³</td>
</tr>
</tbody>
</table>

* HDL-C levels were determined by measuring cholesterol in the supernatant after precipitation of the other lipoproteins by dextran sulfate.

¶ P < 0.05

† P < 0.005 compared to the chow diet.

Figure 1. The effects of the high fat diet on HDL particle size distribution. (A) Native gradient gel electrophoretogram (4–30%) of 30 µl of d < 1.21 g/ml fraction prepared from control or HuAITg plasma on low-fat-low cholesterol or high-fat-high cholesterol diets. As can be seen, control mouse HDL on the low fat-low cholesterol diet consists primarily of a single size population. After the high-fat-high cholesterol diet the pattern is similar, but the peak is broadened and skewed to larger particle diameters. HuAITg HDL on the low fat-low cholesterol diet consists primarily of two distinct HDL subpopulations. After the high fat-high cholesterol diet, the pattern is similar, but there is an increase mainly in the larger HDL subfractions. Molecular mass markers are indicated on the left hand side of the figure. (B) Shows a composite scan of native gradient gel electrophoretogram (4–30%) of 30 µl of d < 1.21 g/ml fraction prepared from HuAITg mice (n = 6) on the low fat-low cholesterol diet and HuAITg mice (n = 5) on the high fat-high cholesterol diet. Gels were scanned individually and analyzed by Gaussian modeling. Results from each group of animals were averaged. As can be seen, the high fat-high cholesterol diet caused a relative increase only in the HDL subfractions of mean particle diameter of ≥ 11 nm.

Hayek, Ito, Azrolan, Verdery, Aalto-Setälä, Walsh, and Breslow

Discussion

Diets high in saturated fat and cholesterol increase the risk of coronary heart disease in humans, yet they raise HDL-C levels (4–9). To study this paradoxical phenomenon a mouse model was created. In this model, animals were studied on a low fat-low cholesterol chow diet and a high fat-high cholesterol Western type diet and dietary fat was shown to increase HDL-C.
levels as it does in humans (4–9). Metabolic turnover studies indicated that the high fat-high cholesterol diet decreased the FCR and increased the TR of HDL CE. The dietary effect was greatest on the HDL CE TR (~60% increase). This is a novel observation that may have significant implications, since HDL is thought to be involved in reverse cholesterol transport (1–3, 29, 30). The current study suggests that the dietary fat–induced increase in HDL-C levels may be an adaptive mechanism reflecting the need for increased flux (HDL CE TR) through the HDL pathway required by the metabolic load of a high-fat-high-cholesterol diet. In our previous metabolic study in humans, HDL-C levels increased 40% when switching from a 10 to a 40% fat diet (9). However, there was a wide range of HDL-C response, from 7 to 68%. It would have been fascinating to observe whether this range of responses of HDL-C levels correlates with differences among people in their ability to increase the flux of HDL CE (HDL CE TR). Humans who fail to respond adequately to a dietary challenge by raising their HDL-C levels and HDL CE TR may be at increased risk of atherosclerosis. Unfortunately, it has not been possible to easily measure HDL CE turnover in humans to study this question (31).

In the mouse model the high fat–high cholesterol diet compared to the low fat–low cholesterol diet was also shown to increase apo A-I levels, decrease apo A-I FCR and increase apo A-I TR. These results are quite comparable to those we previously obtained in humans with a similar dietary change (9). Other clinical investigators, utilizing different dietary protocols, have had different results. Blum studied three females on an extremely low fat liquid formula diet and on a high fat diet, and found a 62% increase in HDL-C levels, which he ascribed to a 32% decrease in HDL apolipoprotein FCR (6). Shepherd studied four males on a 40% fat intake of a polyunsaturated/saturated fat ratio of 4 and 0.25, and found a 48% increase in HDL-C accounted for by a 35% increase in apo A-I TR (7). In animal studies, Quig reported in rabbits that a sixfold increase in saturated fat intake was associated with a twofold increase in HDL apolipoprotein TR without any change in FCR (32). Sorci-Thomas has reported in nonhuman primates on a high cholesterol diet that a change in the polyunsaturated/saturated fat ratio from 2.2 to 0.3 caused a 19% increase in apo A-I levels associated with a 23% increase in hepatic apo A-I production and a 28% increase in hepatic apo A-I mRNA, with no change in intestinal apo A-I mRNA (33). Thus, our own studies in humans and mice and those of others pretty consistently indicate a major effect of dietary fat on the apo A-I TR.

The measurement of apo A-I TR by turnover studies suggests that dietary fat increases hepatic or intestinal production of apo A-I. The line of HuAITg mice used in these experiments produces human apo A-I only in the liver (10). Since dietary fat caused an equal percent increase of human and mouse apo A-I in these mice, it suggests that the effect is exerted mainly on hepatic apo A-I production. Increased hepatic production of apo A-I was corroborated by in vitro labeling studies in which primary liver cell cultures from animals fed the high fat-high cholesterol diet showed increased apo A-I secretion. Srivastava et al. (34) have also shown, using liver slices, that the hepatic production of mouse apo A-I is increased in mice fed a high

**Figure 2.** Effect of the high fat diet on human apo A-I secretion from transgenic mouse primary hepatocytes. HuAITg mice were fed a high fat-high cholesterol diet or a low fat-low cholesterol diet for 4 wk. Primary mouse hepatocytes were then prepared from these animals as described in Methods. These cells were incubated with serum-free medium containing 100 μCi/ml [35S]methionine for the indicated times. An aliquot of conditioned medium from each plate was then immunoprecipitated using an anti-human apo A-I antibody that specifically recognizes only human apo A-I. The immuno-complex was washed and subjected to SDS-PAGE analysis. Gels were then dried and autoradiographed. A representative gel film is shown in the inset. Regions on each gel that corresponded to the apo A-I bands (inset) were excised from the gel and subjected to scintillation counting. Three different gels, each derived from three different sets of dishes were used in each analysis. The experiment shown was performed several (three) times with similar results. Error bars represent SEM (n = 3).

**Table III. Effects of Diet on Hepatic and Intestinal Apo A-I mRNA Levels**

<table>
<thead>
<tr>
<th></th>
<th>Human Apo A-I mRNA</th>
<th>Mouse Apo A-I mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Liver Before/After</td>
<td>Liver Before/After</td>
</tr>
<tr>
<td>Mice</td>
<td>pg/μg total RNA</td>
<td>pg/μg total RNA</td>
</tr>
<tr>
<td>HuAITg (n = 5)</td>
<td>High fat diet</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>254 ± 2</td>
<td>48 ± 3</td>
</tr>
<tr>
<td>Controls (n = 6)</td>
<td>—</td>
<td>51 ± 3</td>
</tr>
</tbody>
</table>

There were no significant differences in hepatic apo A-I mRNA before and after the diet, nor were there any differences in intestinal apo A-I mRNA between HuAITg mice on high fat and low fat diets.

Dietary Fat Increases High Density Lipoprotein Levels 1669
fat-high cholesterol diet. To further localize how dietary fat is acting, apo A-I mRNA levels were measured in tissues from animals on the two contrasting diets and no differences were found. Thus, the effect of dietary fat on apo A-I production is posttranscriptional and could involve increased translatability of the apo A-I mRNA or decreased intracellular degradation of the apo A-I protein. Go et al. have shown increased translatability of rat intestinal apo A-I mRNA with chronic feeding of 2% cholesterol and 0.1% propylthiouracil (35). Davis and others have shown that apo B secretion from hepatocytes is regulated by changes in intracellular degradation (36). Further studies will be necessary to determine exactly the mechanism of the dietary fat effect on apo A-I production.

In humans, a high fat diet causes an increase in the HDL-C to apo A-I ratio and an increase in HDL size (4–9, 37). This also occurred in both the HuAItg and control mice, as shown by chemical analysis and gradient gel electrophoresis. In previous studies in humans, we showed that apo A-I FCR was inversely correlated with HDL size and in a multivariate model HDL size was the best predictor of apo A-I FCR of all the relevant variables tested (38, 39). Thus, in the mouse model the effect of dietary fat on apo A-I and even HDL CE FCR might be mediated by the change in HDL size caused by the diet. It has been suggested that large HDL particles are less easily catabolized, such as through glomerular filtration of apo A-I or liver uptake of HDL particles (40), and this may account for the decrease in FCR.

Previous fat feeding studies in mice have involved toxic diets, such as ones containing 1.25% cholesterol, 15% fat, and the unusual constituent 0.5% cholic acid (14, 35, 41). These diets did not increase HDL-C levels, but rather produced a strain-dependent decrease in HDL-C levels. This is contrary to what one sees in humans placed on a high fat diet and raises questions about the relevance of such diets to the human experience. The current manuscript presents a high fat mouse diet that mimics the human experience and has allowed examination of the mechanism whereby dietary fat influences HDL metabolism.

Acknowledgments

The authors would like to thank Dr. Tova Chajek-Shaul for her expert consultation and for her help in performing some of the turnover studies. We would also like to acknowledge the assistance of Ethel O. Koubi, Ph.D., and Emilio H. Moriguchi, M.D., Ph.D., at the Bowman Gray School of Medicine (Winston-Salem, NC).

This work was supported by J. L. Breslow’s National Institutes of Health grants RO1 HL-32435, RO1HL-33714, and PO1 CA29502, the Calder Foundation, and B. R. Verdeny’s National Institutes of Health grant K01 AG00414.

References